Ivan Špıčka
Impact in
- Hematology top 0.2%
- Multiple Myeloma Research and Treatments
- Oncology top 1%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
Papers in
- Hematology 131
- Multiple Myeloma Research and Treatments 130
- Oncology 64
- Peptidase Inhibition and Analysis 32
- Cancer Treatment and Pharmacology 30
- Co-authors
- Antonio Palumbo (12 shared papers)Andrew Spencer (11 shared papers)Pieter Sonneveld (13 shared papers)María‐Victoria Mateos (25 shared papers)Roman Hájek (59 shared papers)Tamás Masszi (17 shared papers)Meral Beksaç (11 shared papers)Jesús F. San Miguel (23 shared papers)
- Journals
- Journal of Clinical Oncology (28 papers)Blood (26 papers)British Journal of Haematology (8 papers)European Journal Of Haematology (7 papers)Haematologica (5 papers)
- Partner nations
- CzechiaUnited StatesSpain
In The Last Decade
Ivan Špıčka
132 papers receiving 3.8k citations
Ivan Špıčka's Hit Papers
Peers
Comparison fields: 5 of 87
- Hematology 3.1k
- Oncology 1.7k
- Genetics 358
- Molecular Biology 2.0k
- Physiology 52
Countries citing papers authored by Ivan Špıčka
This map shows the geographic impact of Ivan Špıčka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Špıčka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Špıčka more than expected).
Fields of papers citing papers by Ivan Špıčka
This network shows the impact of papers produced by Ivan Špıčka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Špıčka. The network helps show where Ivan Špıčka may publish in the future.
Co-authors
The 25 scholars most cited alongside Ivan Špıčka, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 145 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma Hit paper breakdown → | 2016 | 1086 |
| 2 | Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression Hit paper breakdown → | 2007 | 526 |
| 3 | 2010 | 327 | |
| 4 | 2008 | 156 | |
| 5 | 2014 | 117 | |
| 6 | 2010 | 106 | |
| 7 | 2003 | 105 | |
| 8 | 2022 | 74 | |
| 9 | 2016 | 60 | |
| 10 | 2012 | 58 | |
| 11 | 2020 | 57 | |
| 12 | 2009 | 57 | |
| 13 | 2017 | 50 | |
| 14 | 2017 | 45 | |
| 15 | 2013 | 43 | |
| 16 | 2022 | 42 | |
| 17 | 2016 | 36 | |
| 18 | 2018 | 35 | |
| 19 | 2011 | 35 | |
| 20 | 2022 | 30 |
About Ivan Špıčka
Ivan Špıčka is a scholar working on Hematology, Oncology, Molecular Biology, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 145 papers that have together received 3.9k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (130 papers), Protein Degradation and Inhibitors (38 papers), Peptidase Inhibition and Analysis (32 papers), Cancer Treatment and Pharmacology (30 papers), Chronic Lymphocytic Leukemia Research (18 papers), Cancer therapeutics and mechanisms (12 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (7 papers). The work is most often cited by research in Hematology (3.1k citations), Oncology (1.7k citations), Genetics (358 citations), Molecular Biology (2.0k citations) and Physiology (52 citations). Ivan Špıčka has collaborated with scholars based in Czechia, United States and Spain. Frequent co-authors include Antonio Palumbo, Andrew Spencer, Pieter Sonneveld, María‐Victoria Mateos, Roman Hájek, Tamás Masszi, Meral Beksaç, Jesús F. San Miguel, William Deraedt and Katja Weisel. Their work appears in journals such as Journal of Clinical Oncology, Blood, British Journal of Haematology, European Journal Of Haematology and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.